pharmaceutical news

Johnson & Johnson (JNJ) Stock News & Forecast: EU Drug Approval, $3B Cancer Deal and Dividend Strength – December 1, 2025

As of December 1, 2025. This article is for information only and is not investment advice. JNJ stock today: riding near record highs after a huge 2025 rally Johnson & Johnson (NYSE: JNJ) stock is trading close to its 52‑week

1 December 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted

17 November 2025

Biotechnology · Healthcare Industry · Mergers & Acquisitions · NASDAQ:MTSR · NYSE:PFE · Obesity Treatments · Pharma News

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals, Inc. (NASDAQ: MGRX), the tiny telehealth company best known for its MangoRx men’s wellness brand, is suddenly at the center of the red‑hot obesity drugs market after unveiling a partnership with Eli Lilly and Novo Nordisk to offer official

13 November 2025

Business News · Healthcare · NASDAQ:MGRX · Obesity Treatment · Pharmaceuticals · Stock Market

Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Novo Nordisk cuts Wegovy prices in India up to 37% and faces a pivotal board vote this week, as a U.S. pricing/access deal looms for 2026. Date: November 11, 2025 Key takeaways India: Wegovy gets markedly cheaper — and it’s

11 November 2025

Business News · Drug Pricing · Healthcare Industry · India Market · NYSE:LLY · NYSE:NVO · Pharmaceuticals

GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK plc (NYSE: GSK; LSE: GSK) generated several headlines today: a fresh research tie‑up in tuberculosis drug discovery, confirmation of ongoing share repurchases via a new U.K. regulatory filing, and a U.S.‑listed share price that pushed to a new 12‑month

11 November 2025

Collaborations · Company News · Health Industry · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly and Company (NYSE: LLY) opened the week with a burst of dealmaking and Wall Street momentum. The pharma giant announced a rights deal for a pediatric blindness gene therapy from MeiraGTx, unveiled a new AI‑driven discovery partnership, and

10 November 2025

Artificial Intelligence · Biotech News · Gene Therapy · NASDAQ:ADVM · NASDAQ:MGTX · NASDAQ:NVDA · NYSE:LLY · Pharmaceuticals · Stock Market

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock Soars After $339M BARDA Flu-Drug Deal – Is CD388 the Next Big Flu-Fighter?

Cidara Trading on Oct 3, 2025 On Friday morning Oct 3, CDTX was trading around $104 per share, up roughly 5.7% from Thursday’s close finviz.com. Trading volumes are high as investors digest the Oct 2 BARDA award news. (Finviz shows a sharp jump on Oct

3 October 2025

Biotechnology · İlaç Sektörü · NASDAQ:CDTX · Sağlık · Stock Market · Stocks · Yatırım